The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Primary analysis of the Phase II PILOT study: liso-cel as second-line therapy for R/R LBCL
Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, discusses some key results from the primary analysis of the Phase II PILOT study (NCT03483103) evaluating the use of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Ghosh first discusses the patient population enrolled in this study, including eligibility for transplant and median age. Following this, Dr Ghosh explains the key results from this trial, highlighting the overall response rates (ORR), progression-free survival (PFS) and event-free survival (EFS) observed. To conclude, Dr Ghosh discusses the safety profile of liso-cel in these patients and the toxicities observed, drawing focus on CAR-T therapy-related side effects, such as cytokine release syndrome (CRS) and neurologic events. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding, honoraria, consulting: BMS
Consulting: Lilly, Genentech/Roche
